

# Paul M Young

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4482252/publications.pdf>

Version: 2024-02-01

255  
papers

7,327  
citations

50276

46  
h-index

98798

67  
g-index

259  
all docs

259  
docs citations

259  
times ranked

6302  
citing authors

#	ARTICLE	IF	CITATIONS
1	An adaptable microreactor to investigate the influence of interfaces on <i>Pseudomonas aeruginosa</i> biofilm growth. <i>Applied Microbiology and Biotechnology</i> , 2022, 106, 1067-1077.	3.6	6
2	Prospective nanoparticle treatments for lymphangioliomyomatosis. <i>Expert Opinion on Drug Delivery</i> , 2022, 19, 75-86.	5.0	1
3	Combining experimental and computational techniques to understand and improve dry powder inhalers. <i>Expert Opinion on Drug Delivery</i> , 2022, 19, 59-73.	5.0	8
4	Understanding the effects of aerodynamic and hydrodynamic shear forces on <i>Pseudomonas aeruginosa</i> biofilm growth. <i>Biotechnology and Bioengineering</i> , 2022, 119, 1483-1497.	3.3	9
5	Application of Micro-Engineered Kidney, Liver, and Respiratory System Models to Accelerate Preclinical Drug Testing and Development. <i>Bioengineering</i> , 2022, 9, 150.	3.5	2
6	Toxicity of curcumin nanoparticles towards alveolar macrophage: Effects of surface charges. <i>Food and Chemical Toxicology</i> , 2022, 163, 112976.	3.6	13
7	Investigating potential TRPV1 positive feedback to explain TRPV1 upregulation in airway disease states. <i>Drug Development and Industrial Pharmacy</i> , 2022, , 1-11.	2.0	0
8	Development of excipients free inhalable co-spray-dried tobramycin and diclofenac formulations for cystic fibrosis using two and three fluid nozzles. <i>International Journal of Pharmaceutics</i> , 2022, 624, 121989.	5.2	5
9	In-vitro and particle image velocimetry studies of dry powder inhalers. <i>International Journal of Pharmaceutics</i> , 2021, 592, 119966.	5.2	18
10	Real-time quantitative monitoring of <i>in vitro</i> nasal drug delivery by a nasal epithelial mucosa-on-a-chip model. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 803-818.	5.0	15
11	On the Use of Computational Fluid Dynamics (CFD) Modelling to Design Improved Dry Powder Inhalers. <i>Pharmaceutical Research</i> , 2021, 38, 277-288.	3.5	13
12	Simulation of respiratory tract lining fluid for <i>in vitro</i> dissolution study. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 1091-1100.	5.0	3
13	Development and <i>in vitro</i> characterization of a novel pMDI diclofenac formulation as an inhalable anti-inflammatory therapy for cystic fibrosis. <i>International Journal of Pharmaceutics</i> , 2021, 596, 120319.	5.2	6
14	Increasing the fine particle fraction of pressurised metered dose inhaler solutions with novel actuator shapes. <i>International Journal of Pharmaceutics</i> , 2021, 597, 120341.	5.2	6
15	Tobramycin and Colistin display anti-inflammatory properties in CuFi-1 cystic fibrosis cell line. <i>European Journal of Pharmacology</i> , 2021, 902, 174098.	3.5	2
16	How Do Mechanics Guide Fibroblast Activity? Complex Disruptions during Emphysema Shape Cellular Responses and Limit Research. <i>Bioengineering</i> , 2021, 8, 110.	3.5	6
17	Particle Image Velocimetry Measurements of a Dry Powder Inhaler Flow. <i>International Symposium on Particle Image Velocimetry</i> , 2021, 1, .	0.1	1
18	Development and Evaluation of Paclitaxel and Curcumin Dry Powder for Inhalation Lung Cancer Treatment. <i>Pharmaceutics</i> , 2021, 13, 9.	4.5	34

#	ARTICLE	IF	CITATIONS
19	Inhaled rapamycin solid lipid nano particles for the treatment of Lymphangioleiomyomatosis. European Journal of Pharmaceutical Sciences, 2020, 142, 105098.	4.0	18
20	Selective shape-change response by anisotropic endoskeletal droplets. Extreme Mechanics Letters, 2020, 35, 100618.	4.1	1
21	An in vitro model for assessing drug transport in cystic fibrosis treatment: Characterisation of the CuFi-1 cell line. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 156, 121-130.	4.3	15
22	Properties of rapamycin solid lipid nanoparticles for lymphatic access through the lungs & part I: the effect of size. Nanomedicine, 2020, 15, 1927-1945.	3.3	6
23	Nasal Powder Formulation of Tranexamic Acid and Hyaluronic Acid for the Treatment of Epistaxis. Pharmaceutical Research, 2020, 37, 186.	3.5	9
24	Paclitaxel-eluting silicone airway stent for preventing granulation tissue growth and lung cancer relapse in central airway pathologies. Expert Opinion on Drug Delivery, 2020, 17, 1631-1645.	5.0	7
25	Properties of rapamycin solid lipid nanoparticles for lymphatic access through the lungs & part II: the effect of nanoparticle charge. Nanomedicine, 2020, 15, 1947-1963.	3.3	7
26	Using individualized three-dimensional printed airway models to guide airway stent implantation. Interactive Cardiovascular and Thoracic Surgery, 2020, 31, 900-903.	1.1	4
27	Effect of continuous positive airway pressure treatment on permeability, inflammation and mucus production of human epithelial cells. ERJ Open Research, 2020, 6, 00327-2019.	2.6	6
28	Delivery of pDNA to lung epithelial cells using PLGA nanoparticles formulated with a cell-penetrating peptide: understanding the intracellular fate. Drug Development and Industrial Pharmacy, 2020, 46, 427-442.	2.0	17
29	A Review of Respiratory Anatomical Development, Air Flow Characterization and Particle Deposition. International Journal of Environmental Research and Public Health, 2020, 17, 380.	2.6	68
30	Saturated fatty acids, obesity, and the nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome in asthmatic patients. Journal of Allergy and Clinical Immunology, 2019, 143, 305-315.	2.9	83
31	Co-Spray-Dried Urea Cross-Linked Hyaluronic Acid and Sodium Ascorbyl Phosphate as Novel Inhalable Dry Powder Formulation. Journal of Pharmaceutical Sciences, 2019, 108, 2964-2971.	3.3	11
32	An automated segmentation framework for nasal computational fluid dynamics analysis in computed tomography. Computers in Biology and Medicine, 2019, 115, 103505.	7.0	9
33	Application of a Thermosensitive In Situ Gel of Chitosan-Based Nasal Spray Loaded with Tranexamic Acid for Localised Treatment of Nasal Wounds. AAPS PharmSciTech, 2019, 20, 299.	3.3	38
34	Simvastatin Nanoparticles Reduce Inflammation in LPS-Stimulated Alveolar Macrophages. Journal of Pharmaceutical Sciences, 2019, 108, 3890-3897.	3.3	12
35	Assessing Aerosol Performance of a Dry Powder Carrier Formulation with Increasing Doses Using a Novel Inhaler. AAPS PharmSciTech, 2019, 20, 94.	3.3	7
36	Human Stimulus Factor Is a Promising Peptide for Delivery of Therapeutics. Journal of Pharmaceutical Sciences, 2019, 108, 1401-1403.	3.3	2

#	ARTICLE	IF	CITATIONS
37	Drug distribution transients in solution and suspension-based pressurised metered dose inhaler sprays. <i>International Journal of Pharmaceutics</i> , 2019, 566, 463-475.	5.2	9
38	Smart thermosensitive chitosan hydrogel for nasal delivery of ibuprofen to treat neurological disorders. <i>Expert Opinion on Drug Delivery</i> , 2019, 16, 453-466.	5.0	62
39	Strategies to Enhance Drug Absorption via Nasal and Pulmonary Routes. <i>Pharmaceutics</i> , 2019, 11, 113.	4.5	165
40	Reduced Sleep Quality Correlates with Worse Hyperinflation in Patients with Chronic Obstructive Pulmonary Disease. , 2019, , .		0
41	Eulerâ€“Lagrange approach to investigate respiratory anatomical shape effects on aerosol particle transport and deposition. <i>Toxicology Research and Application</i> , 2019, 3, 239784731989467.	0.6	20
42	The utility of 3D-printed airway stents to improve treatment strategies for central airway obstructions. <i>Drug Development and Industrial Pharmacy</i> , 2019, 45, 1-10.	2.0	33
43	Delivery of pDNA Polyplexes to Bronchial and Alveolar Epithelial Cells Using a Mesh Nebulizer. <i>Pharmaceutical Research</i> , 2019, 36, 14.	3.5	5
44	Effect of Dosing Cup Size on the Aerosol Performance of High-Dose Carrier-Based Formulations in a Novel Dry Powder Inhaler. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 949-959.	3.3	3
45	In vitro characterization of physico-chemical properties, cytotoxicity, bioactivity of urea-crosslinked hyaluronic acid and sodium ascorbyl phosphate nasal powder formulation. <i>International Journal of Pharmaceutics</i> , 2019, 558, 341-350.	5.2	11
46	Limitations of high dose carrier based formulations. <i>International Journal of Pharmaceutics</i> , 2018, 544, 141-152.	5.2	20
47	The use of fatty acids as absorption enhancer for pulmonary drug delivery. <i>International Journal of Pharmaceutics</i> , 2018, 541, 93-100.	5.2	19
48	Microfluidic production of endoskeleton droplets with controlled size and shape. <i>Powder Technology</i> , 2018, 329, 129-136.	4.2	17
49	Sweetening Inhaled Antibiotic Treatment for Eradication of Chronic Respiratory Biofilm Infection. <i>Pharmaceutical Research</i> , 2018, 35, 50.	3.5	11
50	Combination of urea-crosslinked hyaluronic acid and sodium ascorbyl phosphate for the treatment of inflammatory lung diseases: An in vitro study. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 120, 96-106.	4.0	19
51	Is there a role for inhaled anti-inflammatory drugs in cystic fibrosis treatment?. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 69-84.	0.8	3
52	A Simple and Rapid Method for Deposition and Measurement of Drug Transport Across Air Interface Respiratory Epithelia. <i>AAPS PharmSciTech</i> , 2018, 19, 3272-3276.	3.3	5
53	The potential to treat lung cancer via inhalation of repurposed drugs. <i>Advanced Drug Delivery Reviews</i> , 2018, 133, 107-130.	13.7	57
54	Dosing challenges in respiratory therapies. <i>International Journal of Pharmaceutics</i> , 2018, 548, 659-671.	5.2	22

#	ARTICLE	IF	CITATIONS
55	Repurposing of statins via inhalation to treat lung inflammatory conditions. <i>Advanced Drug Delivery Reviews</i> , 2018, 133, 93-106.	13.7	23
56	The Development and Validation of an In Vitro Airway Model to Assess Realistic Airway Deposition and Drug Permeation Behavior of Orally Inhaled Products Across Synthetic Membranes. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2018, 31, 103-108.	1.4	3
57	High-Speed Laser Image Analysis of Plume Angles for Pressurised Metered Dose Inhalers: The Effect of Nozzle Geometry. <i>AAPS PharmSciTech</i> , 2017, 18, 782-789.	3.3	15
58	Investigation into the Manufacture and Properties of Inhalable High-Dose Dry Powders Produced by Comilling API and Lactose with Magnesium Stearate. <i>AAPS PharmSciTech</i> , 2017, 18, 2248-2259.	3.3	4
59	Co-milled API-lactose systems for inhalation therapy: impact of magnesium stearate on physico-chemical stability and aerosolization performance. <i>Drug Development and Industrial Pharmacy</i> , 2017, 43, 980-988.	2.0	21
60	Allergic environment enhances airway epithelial pro-inflammatory responses to rhinovirus infection. <i>Clinical Science</i> , 2017, 131, 499-509.	4.3	18
61	Development of a Soluplus budesonide freeze-dried powder for nasal drug delivery. <i>Drug Development and Industrial Pharmacy</i> , 2017, 43, 1510-1518.	2.0	25
62	The effect of non-specific tight junction modulators on the transepithelial transport of poorly permeable drugs across airway epithelial cells. <i>Journal of Drug Targeting</i> , 2017, 25, 342-349.	4.4	7
63	A review of co-milling techniques for the production of high dose dry powder inhaler formulation. <i>Drug Development and Industrial Pharmacy</i> , 2017, 43, 1229-1238.	2.0	29
64	Revealing pMDI Spray Initial Conditions: Flashing, Atomisation and the Effect of Ethanol. <i>Pharmaceutical Research</i> , 2017, 34, 718-729.	3.5	13
65	The Development and Achievement of Polymeric Nanoparticles for Cancer Drug Treatment. , 2017, , 25-82.		1
66	Drug delivery for tuberculosis: is inhaled therapy the key to success?. <i>Therapeutic Delivery</i> , 2017, 8, 819-821.	2.2	24
67	Inhaled simvastatin nanoparticles for inflammatory lung disease. <i>Nanomedicine</i> , 2017, 12, 2471-2485.	3.3	17
68	The achievement of ligand-functionalized organic/polymeric nanoparticles for treating multidrug resistant cancer. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 937-957.	5.0	21
69	Inhaled gene delivery: a formulation and delivery approach. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 319-330.	5.0	33
70	Novel nano-cellulose excipient for generating non-Newtonian droplets for targeted nasal drug delivery. <i>Drug Development and Industrial Pharmacy</i> , 2017, 43, 1729-1733.	2.0	4
71	Drug Release from Inert Spherical Matrix Systems Using Monte Carlo Simulations. <i>Current Drug Delivery</i> , 2017, 14, 65-72.	1.6	10
72	Motivations and Key Features for a Wearable Device for Continuous Monitoring of Breathing: A Web-Based Survey. <i>JMIR Biomedical Engineering</i> , 2017, 2, e1.	1.2	14

#	ARTICLE	IF	CITATIONS
73	Exploring the impact of sample flowrate on in vitro measurements of metered dose inhaler performance. <i>International Journal of Pharmaceutics</i> , 2016, 514, 420-427.	5.2	6
74	An investigation of surface properties, local elastic modulus and interaction with simulated pulmonary surfactant of surface modified inhalable voriconazole dry powders using atomic force microscopy. <i>RSC Advances</i> , 2016, 6, 25789-25798.	3.6	12
75	The development of a single-use, capsule-free multi-breath tobramycin dry powder inhaler for the treatment of cystic fibrosis. <i>International Journal of Pharmaceutics</i> , 2016, 514, 392-398.	5.2	19
76	Application of RPMI 2650 nasal cell model to a 3D printed apparatus for the testing of drug deposition and permeation of nasal products. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2016, 107, 223-233.	4.3	53
77	A locally constrained statistical shape model for robust nasal cavity segmentation in computed tomography. , 2016, , .		9
78	Synthesis and Characterization of Inhalable Flavonoid Nanoparticle for Lung Cancer Cell Targeting. <i>Journal of Biomedical Nanotechnology</i> , 2016, 12, 371-386.	1.1	38
79	Effect of polyunsaturated fatty acids (PUFAs) on airway epithelial cells' tight junction. <i>Pulmonary Pharmacology and Therapeutics</i> , 2016, 40, 30-38.	2.6	11
80	Resveratrol solid lipid microparticles as dry powder formulation for nasal delivery, characterization and <i>in vitro</i> deposition study. <i>Journal of Microencapsulation</i> , 2016, 33, 735-742.	2.8	12
81	From single excipients to dual excipient platforms in dry powder inhaler products. <i>International Journal of Pharmaceutics</i> , 2016, 514, 374-383.	5.2	35
82	Could simvastatin be considered as a potential therapy for chronic lung diseases? A debate on the pros and cons. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 1407-1420.	5.0	12
83	Primary Air-liquid Interface Culture of Nasal Epithelium for Nasal Drug Delivery. <i>Molecular Pharmaceutics</i> , 2016, 13, 2242-2252.	4.6	44
84	Highly respirable dry powder inhalable formulation of voriconazole with enhanced pulmonary bioavailability. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 183-193.	5.0	27
85	Antibiotic transport across bronchial epithelial cells: Effects of molecular weight, LogP and apparent permeability. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 83, 45-51.	4.0	14
86	Knowledge that people with intellectual disabilities have of their inhaled asthma medications: messages for pharmacists. <i>International Journal of Clinical Pharmacy</i> , 2016, 38, 135-143.	2.1	15
87	Insights into Spray Development from Metered-Dose Inhalers Through Quantitative X-ray Radiography. <i>Pharmaceutical Research</i> , 2016, 33, 1249-1258.	3.5	9
88	The ability of people with intellectual disability to use inhalers – an exploratory mixed methods study. <i>Journal of Asthma</i> , 2016, 53, 86-93.	1.7	9
89	Co-spray dried resveratrol and budesonide inhalation formulation for reducing inflammation and oxidative stress in rat alveolar macrophages. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 86, 20-28.	4.0	35
90	Dry powder nasal drug delivery: challenges, opportunities and a study of the commercial Teijin Puvlizer Rhinocort device and formulation. <i>Drug Development and Industrial Pharmacy</i> , 2016, 42, 1660-1668.	2.0	32

#	ARTICLE	IF	CITATIONS
91	Combination of Silver Nanoparticles and Curcumin Nanoparticles for Enhanced Anti-biofilm Activities. <i>Journal of Agricultural and Food Chemistry</i> , 2016, 64, 2513-2522.	5.2	148
92	Temporally and Spatially Resolved x-ray Fluorescence Measurements of in-situ Drug Concentration in Metered-Dose Inhaler Sprays. <i>Pharmaceutical Research</i> , 2016, 33, 816-825.	3.5	13
93	Cell-based therapies for the treatment of idiopathic pulmonary fibrosis (IPF) disease. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 375-387.	3.1	24
94	Curcumin Nanoparticles Attenuate Production of Pro-inflammatory Markers in Lipopolysaccharide-Induced Macrophages. <i>Pharmaceutical Research</i> , 2016, 33, 315-327.	3.5	16
95	Biological Effects of Simvastatin Formulated as pMDI on Pulmonary Epithelial Cells. <i>Pharmaceutical Research</i> , 2016, 33, 92-101.	3.5	17
96	The role of direct support professionals in asthma management. <i>Journal of Intellectual and Developmental Disability</i> , 2015, 40, 342-353.	1.6	11
97	Unique location but similar issues: working with health professionals in correctional services to improve inhaler use. <i>Journal of Pharmacy Practice and Research</i> , 2015, 45, 276-281.	0.8	1
98	The Effects of Loaded Carrier Mass and Formulation Mass on Aerosolization Efficiency in Dry Powder Inhaler Devices. <i>Current Drug Delivery</i> , 2015, 12, 40-46.	1.6	2
99	The formulation of a pressurized metered dose inhaler containing theophylline for inhalation. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 76, 68-72.	4.0	15
100	Inhalable tranexamic acid for haemoptysis treatment. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 93, 311-319.	4.3	16
101	Beating cilia identification in fluorescence microscope images for accurate CBF measurement. , 2015, , .		1
102	The Formation of Aerosol Particles from Solution-Based Pressurized Metered Dose Inhalers and Implications of Incomplete Droplet Drying: Theoretical and Experimental Comparison. <i>Aerosol Science and Technology</i> , 2015, 49, 1090-1099.	3.1	3
103	Murine pharmacokinetics of rifapentine delivered as an inhalable dry powder. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 319-323.	2.5	14
104	A "soft spot"™ for drug transport: modulation of cell stiffness using fatty acids and its impact on drug transport in lung model. <i>Journal of Materials Chemistry B</i> , 2015, 3, 2583-2589.	5.8	13
105	Implications and emerging control strategies for ventilator-associated infections. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 379-393.	4.4	13
106	Evolved gas analysis during thermal degradation of salbutamol sulphate. <i>Journal of Thermal Analysis and Calorimetry</i> , 2015, 120, 789-794.	3.6	6
107	Mono- and Cocultures of Bronchial and Alveolar Epithelial Cells Respond Differently to Proinflammatory Stimuli and Their Modulation by Salbutamol and Budesonide. <i>Molecular Pharmaceutics</i> , 2015, 12, 2625-2632.	4.6	16
108	In vitro biological activity of resveratrol using a novel inhalable resveratrol spray-dried formulation. <i>International Journal of Pharmaceutics</i> , 2015, 491, 190-197.	5.2	32

#	ARTICLE	IF	CITATIONS
109	Determination of physical and chemical stability in pressurised metered dose inhalers: potential new techniques. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 1661-1675.	5.0	7
110	Is the cellular uptake of respiratory aerosols delivered from different devices equivalent?. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 93, 320-327.	4.3	17
111	Development of an Inhaled Controlled Release Voriconazole Dry Powder Formulation for the Treatment of Respiratory Fungal Infection. <i>Molecular Pharmaceutics</i> , 2015, 12, 2001-2009.	4.6	35
112	Immunomodulatory Effects of a Low-Dose Clarithromycin-Based Macrolide Solution Pressurised Metered Dose Inhaler. <i>Pharmaceutical Research</i> , 2015, 32, 2144-2153.	3.5	13
113	The Effect of Active Pharmaceutical Ingredients on Aerosol Electrostatic Charges from Pressurized Metered Dose Inhalers. <i>Pharmaceutical Research</i> , 2015, 32, 2928-2936.	3.5	5
114	Tuning Aerosol Performance Using the Multibreath Orbital <sup>®</sup> Dry Powder Inhaler Device: Controlling Delivery Parameters and Aerosol Performance via Modification of Puck Orifice Geometry. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 2169-2176.	3.3	11
115	Nano- and micro-based inhaled drug delivery systems for targeting alveolar macrophages. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 1009-1026.	5.0	121
116	Inhalation of nanoparticle-based drug for lung cancer treatment: Advantages and challenges. <i>Asian Journal of Pharmaceutical Sciences</i> , 2015, 10, 481-489.	9.1	133
117	Delivery of theophylline as dry powder for inhalation. <i>Asian Journal of Pharmaceutical Sciences</i> , 2015, 10, 520-527.	9.1	16
118	Solid lipid microparticles as an approach to drug delivery. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 583-599.	5.0	82
119	Multi-breath dry powder inhaler for delivery of cohesive powders in the treatment of bronchiectasis. <i>Drug Development and Industrial Pharmacy</i> , 2015, 41, 859-865.	2.0	20
120	Aerosol particle generation from solution-based pressurized metered dose inhalers: a technical overview of parameters that influence respiratory deposition. <i>Pharmaceutical Development and Technology</i> , 2015, 20, 897-910.	2.4	14
121	The Effect of Actuator Nozzle Designs on the Electrostatic Charge Generated in Pressurised Metered Dose Inhaler Aerosols. <i>Pharmaceutical Research</i> , 2015, 32, 1237-1248.	3.5	4
122	Dry powder formulation of simvastatin. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 857-868.	5.0	22
123	In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 86, 83-89.	4.3	46
124	The formulation, chemical and physical characterisation of clarithromycin-based macrolide solution pressurised metered dose inhaler. <i>Journal of Pharmacy and Pharmacology</i> , 2014, 66, 639-645.	2.4	11
125	Overcoming Dose Limitations Using the Orbital <sup>®</sup> Multi-Breath Dry Powder Inhaler. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2014, 27, 138-147.	1.4	42
126	Towards the bioequivalence of pressurised metered dose inhalers 2. Aerodynamically equivalent particles (with and without glycerol) exhibit different biopharmaceutical profiles in vitro. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 86, 38-45.	4.3	19



#	ARTICLE	IF	CITATIONS
127	The solid-state and morphological characteristics of particles generated from solution-based metered dose inhalers: Influence of ethanol concentration and intrinsic drug properties. <i>Colloids and Surfaces A: Physicochemical and Engineering Aspects</i> , 2014, 443, 345-355.	4.7	16
128	Towards the bioequivalence of pressurised metered dose inhalers 1: Design and characterisation of aerodynamically equivalent beclomethasone dipropionate inhalers with and without glycerol as a non-volatile excipient. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 86, 31-37.	4.3	26
129	Concurrent oral and inhalation drug delivery using a dual formulation system: the use of oral theophylline carrier with combined inhalable budesonide and terbutaline. <i>Drug Delivery and Translational Research</i> , 2014, 4, 256-267.	5.8	7
130	The Influence of Actuator Materials and Nozzle Designs on Electrostatic Charge of Pressurised Metered Dose Inhaler (pMDI) Formulations. <i>Pharmaceutical Research</i> , 2014, 31, 1325-1337.	3.5	10
131	Combined Inhaled Salbutamol and Mannitol Therapy for Mucus Hyper-secretion in Pulmonary Diseases. <i>AAPS Journal</i> , 2014, 16, 269-280.	4.4	25
132	In Vitro Cell Integrated Impactor Deposition Methodology for the Study of Aerodynamically Relevant Size Fractions from Commercial Pressurised Metered Dose Inhalers. <i>Pharmaceutical Research</i> , 2014, 31, 1779-1787.	3.5	33
133	A Rifapentine-Containing Inhaled Triple Antibiotic Formulation for Rapid Treatment of Tubercular Infection. <i>Pharmaceutical Research</i> , 2014, 31, 1239-1253.	3.5	44
134	Across the pulmonary epithelial barrier: Integration of physicochemical properties and human cell models to study pulmonary drug formulations. , 2014, 144, 235-252.		54
135	Investigation into physical&#x2014;chemical variables affecting the manufacture and dissolution of wet-milled clarithromycin nanoparticles. <i>Pharmaceutical Development and Technology</i> , 2014, 19, 911-921.	2.4	7
136	Image-based ciliary beating frequency estimation for therapeutic assessment on defective mucociliary clearance diseases. , 2014, , .		2
137	Non-cytotoxic silver nanoparticle-polyvinyl alcohol hydrogels with anti-biofilm activity: designed as coatings for endotracheal tube materials. <i>Biofouling</i> , 2014, 30, 773-788.	2.2	41
138	A Novel High-Speed Imaging Technique to Predict the Macroscopic Spray Characteristics of Solution Based Pressurised Metered Dose Inhalers. <i>Pharmaceutical Research</i> , 2014, 31, 2963-2974.	3.5	14
139	Novel Simvastatin Inhalation Formulation and Characterisation. <i>AAPS PharmSciTech</i> , 2014, 15, 956-962.	3.3	18
140	Recent advances in curcumin nanoformulation for cancer therapy. <i>Expert Opinion on Drug Delivery</i> , 2014, 11, 1183-1201.	5.0	186
141	Isothermal calorimetry: A predictive tool to model drug-propellant interactions in pressurized metered dose systems. <i>International Journal of Pharmaceutics</i> , 2014, 461, 301-309.	5.2	12
142	A Novel Inhalable Form of Rifapentine. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 1411-1421.	3.3	43
143	Silver nanoparticles enhance <i>Pseudomonas aeruginosa</i> PAO1 biofilm detachment. <i>Drug Development and Industrial Pharmacy</i> , 2014, 40, 719-729.	2.0	43
144	Respiratory medication use in an Australian developmental disability clinic population: messages for health care professionals. <i>Australian Journal of Primary Health</i> , 2014, 20, 278.	0.9	10

#	ARTICLE	IF	CITATIONS
145	Comparison of spray congealing and melt emulsification methods for the incorporation of the water-soluble salbutamol sulphate in lipid microparticles. <i>Pharmaceutical Development and Technology</i> , 2013, 18, 266-273.	2.4	14
146	The effect of ethanol on the formation and physico-chemical properties of particles generated from budesonide solution-based pressurized metered-dose inhalers. <i>Drug Development and Industrial Pharmacy</i> , 2013, 39, 1625-1637.	2.0	26
147	Pharmaceutical applications of the Calu-3 lung epithelia cell line. <i>Expert Opinion on Drug Delivery</i> , 2013, 10, 1287-1302.	5.0	63
148	Salbutamol Sulfate Absorption Across Calu-3 Bronchial Epithelia Cell Monolayer is Inhibited in the Presence of Common Anionic NSAIDs. <i>Journal of Asthma</i> , 2013, 50, 334-341.	1.7	18
149	Quercetin solid lipid microparticles: A flavonoid for inhalation lung delivery. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 49, 278-285.	4.0	53
150	The Effects of Mannitol on the Transport of Ciprofloxacin across Respiratory Epithelia. <i>Molecular Pharmaceutics</i> , 2013, 10, 2915-2924.	4.6	22
151	A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 83, 285-292.	4.3	86
152	Multiple dosing of simvastatin inhibits airway mucus production of epithelial cells: Implications in the treatment of chronic obstructive airway pathologies. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 84, 566-572.	4.3	23
153	Incorporation of quercetin in respirable lipid microparticles: Effect on stability and cellular uptake on A549 pulmonary alveolar epithelial cells. <i>Colloids and Surfaces B: Biointerfaces</i> , 2013, 112, 322-329.	5.0	18
154	Correlation between compactibility values and excipient cluster size using an <i>in silico</i> approach. <i>Drug Development and Industrial Pharmacy</i> , 2013, 39, 374-381.	2.0	1
155	Ciprofloxacin Is Actively Transported across Bronchial Lung Epithelial Cells Using a Calu-3 Air Interface Cell Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2535-2540.	3.2	49
156	Fluticasone uptake across Calu-3 cells is mediated by salmeterol when deposited as a combination powder inhaler. <i>Respirology</i> , 2013, 18, 1197-1201.	2.3	23
157	Delivery of High Solubility Polyols by Vibrating Mesh Nebulizer to Enhance Mucociliary Clearance. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2012, 25, 297-305.	1.4	12
158	Co-deposition of a triple therapy drug formulation for the treatment of chronic obstructive pulmonary disease using solution-based pressurised metered dose inhalers. <i>Journal of Pharmacy and Pharmacology</i> , 2012, 64, 1245-1253.	2.4	17
159	Twenty years of HFA pMDI patents: facts and perspectives. <i>Journal of Pharmacy and Pharmacology</i> , 2012, 64, 1209-1216.	2.4	5
160	Themed Issue: Inhalation Pharmaceutics – Current Technologies and Approaches to Respiratory Drug Delivery. <i>Journal of Pharmacy and Pharmacology</i> , 2012, 64, 1207-1208.	2.4	0
161	Modification of Disodium Cromoglycate Passage Across Lung Epithelium In Vitro Via Incorporation into Polymeric Microparticles. <i>AAPS Journal</i> , 2012, 14, 79-86.	4.4	4
162	Magnetised Thermo Responsive Lipid Vehicles for Targeted and Controlled Lung Drug Delivery. <i>Pharmaceutical Research</i> , 2012, 29, 2456-2467.	3.5	47

#	ARTICLE	IF	CITATIONS
163	Polymer coating of carrier excipients modify aerosol performance of adhered drugs used in dry powder inhalation therapy. <i>International Journal of Pharmaceutics</i> , 2012, 438, 150-159.	5.2	20
164	Parameters affecting drug release from inert matrices. 1: Monte Carlo simulation. <i>Pharmaceutical Development and Technology</i> , 2012, 17, 344-352.	2.4	6
165	Preparation and <i>in vitro</i> evaluation of salbutamol-loaded lipid microparticles for sustained release pulmonary therapy. <i>Journal of Microencapsulation</i> , 2012, 29, 225-233.	2.8	22
166	Deposition, Diffusion and Transport Mechanism of Dry Powder Microparticulate Salbutamol, at the Respiratory Epithelia. <i>Molecular Pharmaceutics</i> , 2012, 9, 1717-1726.	4.6	51
167	Preparation and Evaluation of Single and Co-Engineered Combination Inhalation Carrier Formulations for the Treatment of Asthma. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 4267-4276.	3.3	4
168	Liposomal Nanoparticles Control the Uptake of Ciprofloxacin Across Respiratory Epithelia. <i>Pharmaceutical Research</i> , 2012, 29, 3335-3346.	3.5	75
169	Superhydrophobic, nanotextured polyvinyl chloride films for delaying <i>Pseudomonas aeruginosa</i> attachment to intubation tubes and medical plastics. <i>Acta Biomaterialia</i> , 2012, 8, 1881-1890.	8.3	74
170	The use of computational approaches in inhaler development. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 312-322.	13.7	69
171	The use of inverse gas chromatography for the study of lactose and pharmaceutical materials used in dry powder inhalers. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 285-293.	13.7	53
172	Computational and visualization approaches in respiratory delivery. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 295.	13.7	2
173	Advances in drug delivery: is triple therapy the future for the treatment of chronic obstructive pulmonary disease?. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1913-1932.	1.8	15
174	A Review of Electrostatic Measurement Techniques for Aerosol Drug Delivery to the Lung: Implications in Aerosol Particle Deposition. <i>Journal of Adhesion Science and Technology</i> , 2011, 25, 385-405.	2.6	14
175	Modelling of molecular phase transitions in pharmaceutical inhalation compounds: An <i>in silico</i> approach. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2011, 78, 83-89.	4.3	18
176	Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management. <i>Expert Opinion on Drug Delivery</i> , 2011, 8, 1205-1220.	5.0	45
177	The influence of drug loading on formulation structure and aerosol performance in carrier based dry powder inhalers. <i>International Journal of Pharmaceutics</i> , 2011, 416, 129-135.	5.2	43
178	Particle size dependence of polymorphism in spray-dried mannitol. <i>European Journal of Pharmaceutical Sciences</i> , 2011, 44, 41-48.	4.0	51
179	Epithelial Profiling of Antibiotic Controlled Release Respiratory Formulations. <i>Pharmaceutical Research</i> , 2011, 28, 2327-2338.	3.5	45
180	Does carrier size matter? A fundamental study of drug aerosolisation from carrier based dry powder inhalation systems. <i>International Journal of Pharmaceutics</i> , 2011, 413, 1-9.	5.2	40

#	ARTICLE	IF	CITATIONS
181	Mannitol Delivery by Vibrating Mesh Nebulisation for Enhancing Mucociliary Clearance. Journal of Pharmaceutical Sciences, 2011, 100, 2693-2702.	3.3	13
182	Particle Aerosolisation and Break-Up in Dry Powder Inhalers: Evaluation and Modelling of Impaction Effects for Agglomerated Systems. Journal of Pharmaceutical Sciences, 2011, 100, 2744-2754.	3.3	21
183	Particle Aerosolisation and Break-Up in Dry Powder Inhalers: Evaluation and Modelling of the Influence of Grid Structures for Agglomerated Systems. Journal of Pharmaceutical Sciences, 2011, 100, 4710-4721.	3.3	25
184	Aerosol Tribocharging and its Relation to the Deposition of Oxisâ„¢ TurbuhalerÂ® in the Electrical Next Generation Impactor. Journal of Pharmaceutical Sciences, 2011, 100, 5270-5280.	3.3	5
185	Particle synergy and aerosol performance in non-aqueous liquid of two combinations metered dose inhalation formulations: An AFM and Raman investigation. Journal of Colloid and Interface Science, 2011, 361, 649-655.	9.4	24
186	Dynamic electrostatic charge of lactose-salbutamol sulphate powder blends dispersed from a Cyclohaler <sup>®</sup> . Drug Development and Industrial Pharmacy, 2011, 37, 1365-1375.	2.0	9
187	Understanding lactose behaviour during storage by monitoring surface energy change using inverse gas chromatography. Dairy Science and Technology, 2010, 90, 271-285.	2.2	17
188	The Contribution of Different Formulation Components on the Aerosol Charge in Carrier-Based Dry Powder Inhaler Systems. Pharmaceutical Research, 2010, 27, 1325-1336.	3.5	18
189	Particle Aerosolisation and Break-up in Dry Powder Inhalers 1: Evaluation and Modelling of Venturi Effects for Agglomerated Systems. Pharmaceutical Research, 2010, 27, 1367-1376.	3.5	50
190	Artesunate-clindamycin multi-kinetics and site-specific oral delivery system for antimalaric combination products. Journal of Controlled Release, 2010, 146, 54-60.	9.9	17
191	Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. European Journal of Pharmaceutical Sciences, 2010, 40, 239-247.	4.0	90
192	Does electrostatic charge affect powder aerosolisation?. Journal of Pharmaceutical Sciences, 2010, 99, 2455-2461.	3.3	23
193	Pharmacopeial methodologies for determining aerodynamic mass distributions of ultra-high dose inhaler medicines. Journal of Pharmaceutical and Biomedical Analysis, 2010, 51, 853-857.	2.8	23
194	Time- and passage-dependent characteristics of a Calu-3 respiratory epithelial cell model. Drug Development and Industrial Pharmacy, 2010, 36, 1207-1214.	2.0	98
195	Agglomerate properties and dispersibility changes of salmeterol xinafoate from powders for inhalation after storage at high relative humidity. European Journal of Pharmaceutical Sciences, 2009, 37, 442-450.	4.0	23
196	Measuring charge and mass distributions in dry powder inhalers using the electrical Next Generation Impactor (eNGI). European Journal of Pharmaceutical Sciences, 2009, 38, 88-94.	4.0	47
197	Surface energy changes and their relationship with the dispersibility of salmeterol xinafoate powders for inhalation after storage at high RH. European Journal of Pharmaceutical Sciences, 2009, 38, 347-354.	4.0	30
198	Influence of Storage Relative Humidity on the Dispersion of Salmeterol Xinafoate Powders for Inhalation. Journal of Pharmaceutical Sciences, 2009, 98, 1015-1027.	3.3	27

#	ARTICLE	IF	CITATIONS
199	Preparation and Evaluation of Controlled Release Microparticles for Respiratory Protein Therapy. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 2709-2717.	3.3	34
200	Introduction of the Electrical Next Generation Impactor (eNGI) and Investigation of its Capabilities for the Study of Pressurized Metered Dose Inhalers. <i>Pharmaceutical Research</i> , 2009, 26, 431-437.	3.5	32
201	Lactose Composite Carriers for Respiratory Delivery. <i>Pharmaceutical Research</i> , 2009, 26, 802-810.	3.5	49
202	Pulmonary Spray Dried Powders of Tobramycin Containing Sodium Stearate to Improve Aerosolization Efficiency. <i>Pharmaceutical Research</i> , 2009, 26, 1084-1092.	3.5	56
203	The Influence of Flow Rate on the Aerosol Deposition Profile and Electrostatic Charge of Single and Combination Metered Dose Inhalers. <i>Pharmaceutical Research</i> , 2009, 26, 2639-2646.	3.5	36
204	Development of an In Vivo Ovine Dry Powder Inhalation Model for the Evaluation of Conventional and Controlled Release Microparticles. <i>AAPS Journal</i> , 2009, 11, 465-8.	4.4	7
205	Solid Lipid Budesonide Microparticles for Controlled Release Inhalation Therapy. <i>AAPS Journal</i> , 2009, 11, 771-778.	4.4	64
206	The influence of micronised particulates on the aerosolisation properties of pressurised metered dose inhalers. <i>Journal of Aerosol Science</i> , 2009, 40, 324-337.	3.8	11
207	Delivery of antibiotics to the respiratory tract: an update. <i>Expert Opinion on Drug Delivery</i> , 2009, 6, 897-905.	5.0	76
208	Recent Advances in Controlled Release Pulmonary Therapy. <i>Current Drug Delivery</i> , 2009, 6, 404-414.	1.6	22
209	The Influence of Drug Morphology on Aerosolisation Efficiency of Dry Powder Inhaler Formulations. <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 2780-2788.	3.3	74
210	Role of Agglomeration in the Dispersion of Salmeterol Xinafoate from Mixtures for Inhalation with Differing Drug to Fine Lactose Ratios. <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 3140-3152.	3.3	35
211	Cospray Dried Antibiotics for Dry Powder Lung Delivery. <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 3356-3366.	3.3	67
212	The use of atomic force microscopy to study the conditioning of micronised budesonide. <i>International Journal of Pharmaceutics</i> , 2008, 357, 314-317.	5.2	13
213	Surface Energy of Microcrystalline Cellulose Determined by Capillary Intrusion and Inverse Gas Chromatography. <i>AAPS Journal</i> , 2008, 10, 494-503.	4.4	40
214	Microstructural Analysis of Porous Composite Materials: Dynamic Imaging of Drug Dissolution and Diffusion Through Porous Matrices. <i>AAPS Journal</i> , 2008, 10, 560-564.	4.4	11
215	Determination of Reference Ultrasound Parameters for Model and Hydrofluoroalkane Propellants Using High-Resolution Ultrasonic Spectroscopy. <i>AAPS PharmSciTech</i> , 2008, 9, 605-611.	3.3	2
216	Micro-particle corrugation, adhesion and inhalation aerosol efficiency. <i>European Journal of Pharmaceutical Sciences</i> , 2008, 35, 12-18.	4.0	80

#	ARTICLE	IF	CITATIONS
217	The Influence of Lactose Pseudopolymorphic Form on Salbutamol Sulfate's Lactose Interactions in DPI Formulations. <i>Drug Development and Industrial Pharmacy</i> , 2008, 34, 992-1001.	2.0	90
218	Composite carriers improve the aerosolisation efficiency of drugs for respiratory delivery. <i>Journal of Aerosol Science</i> , 2008, 39, 82-93.	3.8	39
219	Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 1: Influence of polymer concentration on physical and in vitro characteristics. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 69, 486-495.	4.3	35
220	Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 2: Evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 70, 145-152.	4.3	90
221	Comparative Measurements of Pressurised Metered Dose Inhaler (pMDI) Stem Displacement. <i>Drug Development and Industrial Pharmacy</i> , 2008, 34, 90-94.	2.0	2
222	Scanning White-Light Interferometry as a Novel Technique to Quantify the Surface Roughness of Micron-Sized Particles for Inhalation. <i>Langmuir</i> , 2008, 24, 11307-11312.	3.5	25
223	The Use of Organic Vapor Sorption to Determine Low Levels of Amorphous Content in Processed Pharmaceutical Powders. <i>Drug Development and Industrial Pharmacy</i> , 2007, 33, 91-97.	2.0	40
224	Interaction of Moisture with Sodium Starch Glycolate. <i>Pharmaceutical Development and Technology</i> , 2007, 12, 211-216.	2.4	5
225	Effect of Moisture on the Compressibility and Compactibility of Sodium Starch Glycolate. <i>Pharmaceutical Development and Technology</i> , 2007, 12, 217-222.	2.4	2
226	The Influence of Mechanical Processing of Dry Powder Inhaler Carriers on Drug Aerosolization Performance. <i>Journal of Pharmaceutical Sciences</i> , 2007, 96, 1331-1341.	3.3	60
227	Influence of Humidity on the Electrostatic Charge and Aerosol Performance of Dry Powder Inhaler Carrier based Systems. <i>Pharmaceutical Research</i> , 2007, 24, 963-970.	3.5	103
228	Recent advances in understanding the influence of composite-formulation properties on the performance of dry powder inhalers. <i>Physica B: Condensed Matter</i> , 2007, 394, 315-319.	2.7	8
229	A Novel Apparatus for the Determination of Solubility in Pressurized Metered Dose Inhalers. <i>Drug Development and Industrial Pharmacy</i> , 2006, 32, 1159-1163.	2.0	15
230	Novel Temperature Controlled Surface Dissolution of Excipient Particles for Carrier Based Dry Powder Inhaler Formulations. <i>Drug Development and Industrial Pharmacy</i> , 2006, 32, 243-251.	2.0	34
231	Continued Investigation Into the Influence of Loaded Dose on the Performance of Dry Powder Inhalers: Surface Smoothing Effects. <i>Drug Development and Industrial Pharmacy</i> , 2006, 32, 1135-1138.	2.0	38
232	Investigation into the influence of polymeric stabilizing excipients on inter-particulate forces in pressurised metered dose inhalers. <i>International Journal of Pharmaceutics</i> , 2006, 320, 58-63.	5.2	27
233	Agglomerate Strength and Dispersion of Salmeterol Xinafoate from Powder Mixtures for Inhalation. <i>Pharmaceutical Research</i> , 2006, 23, 2556-2565.	3.5	76
234	In Vitro Investigation of Drug Particulates Interactions and Aerosol Performance of Pressurised Metered Dose Inhalers. <i>Pharmaceutical Research</i> , 2006, 24, 125-135.	3.5	30

#	ARTICLE	IF	CITATIONS
235	Comparative study of erythritol and lactose monohydrate as carriers for inhalation: Atomic force microscopy and in vitro correlation. <i>European Journal of Pharmaceutical Sciences</i> , 2006, 27, 243-251.	4.0	36
236	The use of colloid probe microscopy to predict aerosolization performance in dry powder inhalers: AFM and in vitro correlation. <i>Journal of Pharmaceutical Sciences</i> , 2006, 95, 1800-1809.	3.3	29
237	The Use of AFM and Surface Energy Measurements to Investigate Drug-Canister Material Interactions in a Model Pressurized Metered Dose Inhaler Formulation. <i>Aerosol Science and Technology</i> , 2006, 40, 227-236.	3.1	28
238	The influence of dose on the performance of dry powder inhalation systems. <i>International Journal of Pharmaceutics</i> , 2005, 296, 26-33.	5.2	108
239	On the physical transformations of processed pharmaceutical solids. <i>Micron</i> , 2005, 36, 519-524.	2.2	40
240	Surface Energy and Interparticle Force Correlation in Model pMDI Formulations. <i>Pharmaceutical Research</i> , 2005, 22, 816-825.	3.5	54
241	Dynamic Vapor Sorption Properties of Sodium Starch Glycolate Disintegrants. <i>Pharmaceutical Development and Technology</i> , 2005, 10, 249-259.	2.4	26
242	Dynamic Vapor Sorption Properties of Sodium Starch Glycolate Disintegrants. <i>Pharmaceutical Development and Technology</i> , 2005, 10, 249-259.	2.4	4
243	The Development of a Novel High-Dose Pressurized Aerosol Dry-Powder Device (PADD) for the Delivery of Pumactant for Inhalation Therapy. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2004, 17, 123-128.	1.2	22
244	The influence of humidity on the aerosolisation of micronised and SEDS produced salbutamol sulphate. <i>European Journal of Pharmaceutical Sciences</i> , 2004, 22, 235-240.	4.0	66
245	The surface roughness of lactose particles can be modulated by wet-smoothing using a high-shear mixer. <i>AAPS PharmSciTech</i> , 2004, 5, 69-74.	3.3	57
246	Visualization of the crystallization of lactose from the amorphous state. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 155-164.	3.3	108
247	The Influence of Relative Humidity on the Cohesion Properties of Micronized Drugs Used in Inhalation Therapy. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 753-761.	3.3	51
248	The potential use of raman mapping to investigate in vitro deposition of combination pressurized metered-dose inhalers. <i>AAPS Journal</i> , 2004, 6, 41-44.	4.4	17
249	Investigation into the Effect of Humidity on Drug-Drug Interactions Using the Atomic Force Microscope. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 815-822.	3.3	70
250	The Effect of Mechanical Processing on Surface Stability of Pharmaceutical Powders: Visualization by Atomic Force Microscopy. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 611-620.	3.3	45
251	Under pressure: predicting pressurized metered dose inhaler interactions using the atomic force microscope. <i>Journal of Colloid and Interface Science</i> , 2003, 262, 298-302.	9.4	43
252	Effect of Humidity on Aerosolization of Micronized Drugs. <i>Drug Development and Industrial Pharmacy</i> , 2003, 29, 959-966.	2.0	45

#	ARTICLE	IF	CITATIONS
253	Chemical characterisation of sodium starch glycolate particles. International Journal of Pharmaceutics, 2002, 240, 67-78.	5.2	20
254	The influence of relative humidity on particulate interactions in carrier-based dry powder inhaler formulations. International Journal of Pharmaceutics, 2002, 246, 47-59.	5.2	144
255	Characterization of the surface physico-chemical stability of materials directly applicable to inhalation therapy. , 0, , .		1